Our Solutions

Gain strategic, in-depth insights across your product’s lifecycle.

MMS is the trusted, data-focused clinical research organization (CRO) chosen by Sponsors across the globe for our dedication to providing comprehensive, integrated solutions in all aspects of drug development. Our expertise spans regulatory submissions support from pre-IND to marketing authorization, comprehensive safety solutions, full-service biometrics management and execution, and functional service provider (FSP) models, with a deep bench of therapeutic area expertise.

We believe in delivering strategic, in-depth insights which focus on the long-term success of our customers and their assets. This holistic approach ensures that every aspect of your drug development process is meticulously managed, from initial IND submissions through to marketing authorization approvals and post-approval activities. What sets MMS apart is our unwavering focus on data-driven methodologies and a commitment to delivering tailored, end-to-end solutions that are necessary to drive your programs and projects to success. The result is successful outcomes for our customers and the best customer satisfaction and employee stability in the industry.

Explore our solutions to see how MMS can help you achieve your drug development goals with confidence and precision.

Suggested For You

news

April 3rd, 2025

Datacise by MMS Wins 2025 Data Breakthrough Award for Best Data Science Solution

perspectives

March 27th, 2025

Enhancing Drug Safety Through Digital Solutions: Innovative Technologies in FDA REMS Programs

news

March 19th, 2025

MMS REMS-focused Technology bolsters Full-Service REMS Solutions

webinar

April 30th, 2025

Advancing Clinical Development with Innovative Trial Design and Regulatory Strategies

perspectives

March 6th, 2025

Overview of FDA Guidance for Industry on Assessment of Ovarian Toxicity in Premenopausal Adults During Development for Oncologic Products

webinar

March 25th, 2025

Overcoming NDA/BLA Submission Challenges: Practical Strategies for Success

perspectives

February 13th, 2025

Helping European Drug Development Companies Succeed in the US Market

news

February 12th, 2025

MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO

perspectives

January 30th, 2025

Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned

perspectives

January 21st, 2025

REMS Modifications and Revisions: A Retrospective from the Past 12 Months

regulatory intelligence

January 17th, 2025

The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development

regulatory intelligence

January 17th, 2025

New FDA Protocol Deviation Guidance:  Planning for the Things That Don’t Go According to Plan